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Although the anti-cancer properties of 3BP (3-bromopyruvate)
have been described previously, its selectivity for cancer cells still
needs to be explained [Ko et al. (2001) Cancer Lett. 173, 83–91].
In the present study, we characterized the kinetic parameters of
radiolabelled [14C] 3BP uptake in three breast cancer cell lines
that display different levels of resistance to 3BP: ZR-75-1 <
MCF-7 < SK-BR-3. At pH 6.0, the affinity of cancer cells for
3BP transport correlates with their sensitivity, a pattern that does
not occur at pH 7.4. In the three cell lines, the uptake of 3BP is
dependent on the protonmotive force and is decreased by MCTs
(monocarboxylate transporters) inhibitors. In the SK-BR-3 cell
line, a sodium-dependent transport also occurs. Butyrate promotes
the localization of MCT-1 at the plasma membrane and increases
the level of MCT-4 expression, leading to a higher sensitivity for
3BP. In the present study, we demonstrate that this phenotype is
accompanied by an increase in affinity for 3BP uptake. Our results
confirm the role of MCTs, especially MCT-1, in 3BP uptake and
the importance of cluster of differentiation (CD) 147 glycosylation
in this process. We find that the affinity for 3BP transport is higher
when the extracellular milieu is acidic. This is a typical phenotype
of tumour microenvironment and explains the lack of secondary
effects of 3BP already described in in vivo studies [Ko et al. (2004)
Biochem. Biophys. Res. Commun. 324, 269–275].
Key words: 3-bromopyruvate, cluster of differentiation (CD)
147, extracellular acid pH, lactate, monocarboxylate transporter,
tumour microenvironment.
INTRODUCTION
Cancer cells acquire de novo features different from normal
cells, commonly referred as ‘hallmarks’ [1]. Unravelling these
hallmarks is of extreme importance in understanding how cancer
cells behave and subsequently for developing new methods for
diagnosis and therapy. One such hallmark first described by
Otto Warburg [2] as the origin of cancer cells is the acquisition
of an aerobic glycolytic phenotype, i.e. the metabolism of the
sugar glucose to lactic acid, even in the presence of oxygen.
The resultant cancer cells, even in the presence of oxygen, rely
somewhat more on glycolysis for energy production than normal
cells but also carry out oxidative phosphorylation (OXPHOS)
[3]. The elevated glycolytic rate even in the presence of oxygen
resulting from this metabolic reprogramming is known as the
‘Warburg effect’ and, together with mitochondrial OXPHOS,
is crucial for the rapid energy production that sustains high
proliferative rates, providing biosynthetic precursors that support
cell growth [4].
The enhanced glycolysis in cancer cells correlates with an
increased expression of enzymes, e.g. hexokinase 2 (Hk-2)
[5,6] and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
[7], as well as transporters for glucose (GLUTs) [8] and
lactate [MCTs (monocarboxylate transporters) [9,10]. Whereas
GLUTs are important for the increased uptake of the glucose
needed to sustain high rates of glycolysis, Hk-2 bound to
the outer mitochondrial membrane rapidly phosphorylates the
glucose to glucose 6-phosphate without the negative feedback
observed for other hexokinase isoforms [11]. Significantly, Hk-2
is bound to the outer mitochondrial membrane via the porin-like
protein VDAC (voltage-dependent anion channel). The adenine
nucleotide transporter located in the inner membrane and VDAC
in the outer membrane move ATP made by the mitochondrial
inner membrane ATP synthase to the active site of Hk-2 bound to
VDAC. Here, the ATP and glucose are converted into glucose
6-phosphate at an elevated rate. This critical metabolite then
serves as both a biosynthetic precursor to support cell proliferation
(via the pentose phosphate pathway) and via the glycolytic
pathway as a precursor for lactate that, upon export, reduces
the extracellular pH, an event that probably contributes to the
proliferation, invasion, metastasis and angiogenesis of tumour
cells [6].
The high level of lactate produced via glycolysis in cancer cells
needs to be exported in order to avoid intracellular acidification
and cell death. Therefore, cancer cells commonly overexpress
MCTs [9,10]. MCTs are a family of transmembrane transporters
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composed of 14 members but only MCT-1, -2, -3 and -4 are
known to participate in uptake and efflux of monocarboxylic
acids via a proton-linked mechanism [12]. Whereas MCT-1 is
expressed ubiquitously and is known to participate either in the
uptake or in the efflux of lactate, MCT-4 is largely described as
a lactate exporter. Both MCT-1 and MCT-4 are overexpressed in
many tumours and are normally associated with their chaperone
cluster of differentiation (CD) 147 [10,13-16]. CD147 needs to be
glycosylated to reach the plasma membrane, otherwise it will be
retained at the endoplasmic reticulum [17]. MCT-2 is a high-
affinity lactate transporter that is overexpressed in cancer but
only at the cytoplasmic level [10,16]. MCT-3 has a restricted
expression in the retina [18] and has never been associated
with cancer-related processes. MCTs have been described as
good histological markers for cancer prognosis. They have been
mentioned also as targets for therapeutic candidates either by
inhibition of lactate efflux using inhibitors such as α-cyano-
4-hydroxycinnamic acid (CHC) [19] and AR-C155858 [20], a
specific MCT-1 inhibitor, or through the silencing of MCT gene
expression [21].
MCTs can be used also for cancer therapy as Trojan horses for
toxic molecules recognized as substrates for MCT transport. One
such molecule is 3-bromopyruvate (3BP), an analogue of lactate
and pyruvate that is known for its alkylating properties. 3BP
targets energy metabolism of cancer cells, i.e. both glycolysis and
mitochondrial oxidative phosphorylation, while leaving normal
cells unharmed. Glycolytic targets of 3BP are both Hk-2 [22]
and GAPDH [23]. 3BP’s anti-tumour efficiency has been proven
in vitro for different tumour models and also in vivo [22,24].
Significantly, 3BP completely eradicated cancers (hepatomas) in
19 of 19 rats (100%) without any noticeable secondary effects
[24]. Moreover, all animals lived out a normal life without the
return of cancer. Also, 3BP has been used successfully in a
human translational study [25] significantly extending the life
of the patient. These remarkable findings warrant clinical trials
involving multiple patients to fully evaluate 3BP’s potential as an
anti-cancer agent.
Due to the alkylating properties of 3BP, it is surprising that few
secondary effects have been reported to date. This may be related
to the structural similarity of 3BP to the monocarboxylic acids
lactate and pyruvate that make it suitable for transport by the MCT
or MCTs overexpressed in most tumours. Thus, 3BP may enter
cancer cells on the same MCT on which lactate makes its exit.
One study conducted by Birsoy et al. [26] reported the importance
of MCTs, e.g. MCT-1, in facilitating 3BP’s anticancer properties.
We have shown also that 3BP’s cytotoxic effect correlates with
MCT expression level and that cell sensitivity to 3BP can be
increased by pretreatment with butyrate. This leads to an increased
expression of MCT-4 and enhances localization of MCT-1 at
the plasma membrane [27]. Other studies have also reported the
capacity of SMCT-1 (sodium monocarboxylate transporter), a
sodium-dependent electrogenic transporter of monocarboxylates,
in facilitating the uptake of 3BP despite the fact that its expression
is down-regulated in cancer cells [28].
Based on all that described above, it seems clear that
previous studies have provided many clues underlying the
importance of MCTs in facilitating the anti-cancer properties of
3BP [26,27]. However, the kinetics of 3BP’s transport across
the plasma membrane at physiological and tumour-associated
extracellular pH has not been reported. In the present study
using [14C] 3BP, we carried out a detailed characterization
of the kinetics and energetics of 3BP transport with the
objective of understanding how its transport correlates with
its cytotoxic effect in cancer cells while leaving normal cells
unharmed.
Table 1 List of primary and secondary antibodies conditions used in the
present study
Protein Size (kDa) Supplier; dilution (diluent)
MCT-1 43 Santa Cruz Biotechnology; 1:500 (5 % milk)
MCT-4 43 Santa Cruz Biotechnology; 1:500 (5 % BSA)
AE1 102 Abcam; 1:500 (5 % milk)
CD147 45–65 (FG) Santa Cruz Biotechnology; 1:100 (5 % milk)
35 (CG) –
CD44 83 Serotec; 1:500 (5 % milk)
Hk-2 102 Abcam; 1:759 (5 % milk)
β-Actin 30 Santa Cruz Biotechnology; 1:2000 (5 % BSA)
MATERIAL AND METHODS
Cell lines and culture conditions
Three breast cancer cell lines were obtained from the A.T.C.C.:
MCF-7, ZR-75-1 and SK-BR-3. All cell lines were grown as
monolayers at 37 ◦C in a humidified incubator with 5% CO2 and
in RPMI 1640 medium (PAA Laboratories GmbH) supplemented
with 10% FBS (Invitrogen) and 1% penicillin/streptomycin
(Invitrogen). The medium for MCF-7 was also supplemented with
25 μg/ml insulin (Sigma). Cells were kept in exponential growth
phase and subcultured twice a week. For assays, subconfluent cells
in exponential growth phase were detached with trypsin/EDTA
(Invitrogen) and resuspended in fresh medium at the appropriate
density.
Chemicals
3BP, butyric acid, lactic acid and tunicamycin were purchased
from Sigma. Acetic acid and pyruvic acid were purchased from
Merck. Radiolabelled [14C] 3BP, with a specific activity of 15.0
mCi/mmol was purchased from PerkinElmer. Carbonyl cyanide
m-chlorophenyl hydrazone (CCCP), monensin, valinomycin and
CHC were purchased from Sigma. 4,4′-Di-isothiocyano-2,2′-
stilbenedisulfonic acid (DIDS) was obtained from Santa Cruz
Biotechnology and AR-C155858 was a gift from AstraZeneca.
The origins of the antibodies used for Western blot analysis, as
well as the dilutions used, are described in Table 1.
Measurement of 3BP uptake
The protocol for [14C] 3BP uptake was adapted from that of
Kobayashi et al. [29]. Briefly, cells seeded in 24-well plates
at 2–3 × 105 cells/well and incubated overnight at 37 ◦C with
5% CO2 were washed twice and incubated with HEPES
buffer (pH 7.4) (25 mM D-glucose, 137 mM NaCl, 5.37 mM
KCl, 0.3 mM Na2HPO4, 0.44 mM KH2PO4, 4.17 mM NaHCO3,
1.26 mM CaCl2, 0.8 mM MgSO4 and 10 mM HEPES) for 10 min
at 37 ◦C. HEPES buffer was removed and cells were incubated in
MES buffer (pH 6.0) (25 mM D-glucose, 137 mM NaCl, 5.37 mM
KCl, 0.3 mM Na2HPO4, 0.44 mM KH2PO4, 4.17 mM NaHCO3,
1.26 mM CaCl2, 0.8 mM MgSO4 and 10 mM MES) with the
radiolabelled [14C] 3BP (4000 d.p.m./nmol) for the appropriate
period of time at 37 ◦C. Uptake was performed in [14C] 3BP
HEPES buffer (pH 7.4).
After the appropriate incubation time, the [14C] 3BP solution
was removed, the plate was incubated on ice and the cultures
washed with ice-cold HEPES buffer, pH 7.4. Cells were then
solubilized with 1% SDS/0.2 M NaOH and mixed with
scintillation liquid for measuring radioactivity in a Packard
Tri-Carb 2200 CA liquid scintillation spectrophotometer with
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d.p.m. correction. For normalization, protein of all samples was
quantified using a BCA Protein Assay Kit (Pierce). Kinetic
parameters were determined using GraphPad Prism 4 software
for the non-linear regression of the plots of the initial uptake
rates of 3BP as a function of the acid concentration. As [14C]
3BP uptake was linear up to 30 min, 15 min of incubation of the
cells with the radio labelled substrate was adopted in the present
study.
The effect of distinct inhibitors AR-C155858, CHC, DIDS,
CCCP, monensin and valinomycin was evaluated in cells
incubated for 3 min with each compound in MES buffer, pH 6.0,
prior to incubation with 1.0 mM [14C] 3BP for 15 min. The
inhibitory effect of lactate and pyruvate (10 mM) was evaluated
by mixing each acid with 1.0 mM [14C] 3BP in MES buffer,
pH 6.0.
Butyrate pretreatment
Cells were seeded at 1.5 × 105 cells/well in a 24-well plate and
allowed to attach overnight. Then, the medium was replaced
by fresh medium containing butyrate at 10 mM. After 24 h
of incubation, the kinetics of 3BP uptake was evaluated. Cells
cultivated under the same conditions, but without the addition of
butyrate, were used as a control.
SRB cell survival assay
After 24 h of growth in RPMI 1640 medium, the cells seeded in
96-well plates, were treated with a series of 3BP concentrations in
RPMI 1640 medium buffered with HEPES at pH 6.0 and 7.4. To
the evaluation of the effect of AR-C155858 on 3BP cytotoxicity,
the compound was added to different concentrations of 3BP in
RPMI 1640 medium. After 16 h of treatment, cells were fixed
with a solution of 1.0% acetic acid in methanol for 90 min
at − 20 ◦C. After washing with PBS and air-drying, the fixed
cells were stained with 0.4% sulforodamine B (SRB; Sigma) for
90 min at 37 ◦C. Cells were then rinsed with 1.0% acetic acid and
air-dried. The bound dye was solubilized with 10 mM Tris/HCl
and the absorbance was measured at 540 nm. The percentage of
surviving cells was determined by comparing the absorbance of
the treated cells to the untreated cells (corresponding to 100% of
viable cells) for each pH. At least three independent experiments
were performed, each in triplicate and IC50 values were estimated
using GraphPad Prism 4 software, applying a sigmoidal dose-
response (variable slope) non-linear regression, after logarithmic
transformation.
Protein expression analysis
The expression of MCT-1, MCT-4, CD147, CD44, AE1 and Hk-2
was assessed by Western blot analysis. Cells were seeded in 60-
mm plates at 1.5–2.0 × 106 cells/plate and incubated at 37 ◦C,
5% CO2. After 24 h, cells were washed with ice-cold PBS,
collected by scrapping and then centrifuged at 2000 g for 5 min.
Supernatants were discarded and ice-cold lysis buffer [150 mM
NaCl, 0.1 mM EDTA, 1% Triton X-100, 1% NP40, 50 mM
Tris/HCl, pH 7.5 and 1/7 protease inhibitor cocktail (Roche
Applied Sciences)] was added. The lysates were incubated at
4 ◦C for 15 min and then centrifuged at 13000 g for 15 min.
Supernatants were collected for protein analysis and quantified
using the Pierce BCA Protein Assay Kit.
Western blot analysis was performed according to conventional
protocols. Protein samples were separated by 10% acrylamide
SDS/PAGE and after separation, transferred on to PVDF
membranes (Millipore). When the transfer was completed,
membranes were washed in PBS with 0.1% Tween 20 (PBST)
and blocked in 5.0% skimmed milk solution for 1 h at room
temperature. After proper rinsing in PBST, the membranes
were incubated over-night at 4 ◦C with primary antibodies for
the proteins described above. The antibody dilutions used are
presented in Table 1. Then, membranes were washed three
times with PBS and incubated for 1 h at room temperature
with the proper secondary antibody, conjugated with horseradish
peroxidase. The immunoreactive proteins were visualized using
the enhanced chemiluminescence detection kit (Millipore), in
an imaging system (Chemidoc, Bio-Rad Laboratories). Protein
content was analysed using ImageJ software (NIH) by measuring
the density of each band and then normalizing to the actin content.
Tunicamycin inhibition of CD147
The inhibition of CD147 glycosylation was obtained using
tunicamycin, an inhibitor of N-glycosylation in ZR-75-1 cell line.
Cells were seeded in 24- and six-well plates for 3BP uptake assays
and protein expression analysis respectively, as already described.
After overnight incubation to allow cell attachment, the medium
was replaced by fresh medium containing crescent concentrations
of tunicamycin (0, 2, 5, 10 and 20 μg/ml). Cells were incubated
for 48, 72 and 96 h and further used for 3BP uptake and protein
extraction for Western blot analysis.
Statistical analysis
To evaluate the differences in the kinetic parameters (Km and Vmax)
of each cell line, a one-way ANOVA with Tukey’s post-test was
used. For analysing the results of the inhibition of 3BP uptake
were utilized a one-way ANOVA with Dunnett’s post-hoc test
comparing all drug to the control. The effect of tunicamycin in
the 3BP uptake inhibition was analysed by two-way ANOVA.
RESULTS
Kinetics and energetics of 3BP uptake across the plasma
membrane in breast cancer cell lines
The initial uptake rates of [14C] 3BP at pH 6.0 and pH 7.4
(Figure 1) evaluated in ZR-75-1, MCF-7 and SK-BR-3 breast
cancer cell lines followed Michaelis–Menten-like kinetic profiles.
At pH 7.4, no statistical significance was found for variations
detected both in Km and in Vmax values for the three cell
lines. Regarding the capacity for 3BP transport at pH 6.0, the
distinct values for Vmax showed no statistically valid difference.
However, at pH 6.0, the Km for 3BP uptake in SK-BR-3 was
2.11 +− 0.62 mM, a value significantly higher (P < 0.05) than those
estimated for the ZR-75-1 and MCF-7 cell lines, 0.57 +− 0.16 mM
and 0.70 +− 0.12 mM respectively. These results indicate that the
affinity for 3BP transport at acidic pH is distinct in the different
breast cancer cell lines.
To evaluate the energetics of [14C] 3BP transport we
tested the influence of different agents known to disrupt
the membrane electrochemical potentials (Figure 2), such as
CCCP (a protonophore which disrupts both the pH and the
electric potentials), monensin (an ionophore that specifically
disrupts an Na+ gradient) and valinomycin (an ionophore which
preferentially affects a K+ gradient and, to a lesser extent, an Na+
gradient across biological membranes).
CCCP impaired 3BP uptake in all cell lines (Figure 2, light grey
bars), with a more pronounced effect in the SK-BR-3 cells. Here,
c© The Authors Journal compilation c© 2015 Biochemical Society
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Figure 1 Kinetics of radiolabelled 3BP uptake at pH 6.0 and 7.4 in breast cancer cell lines ZR-75-1, MCF-7 and SK-BR-3
(A and B) Plots of the initial uptake rates of radio labelled 3BP as a function of the acid concentration at pH 6.0 (A) and pH 7.4 (B). (C) Kinetic parameters, as affinity constant (K m) and transport
capacity (V max) for the uptake of 3BP. Values were estimated with GraphPad Prism software based on the non-linear regression for the Michaelis–Menten equation f [V] = (V max × [3BP])/(K m +
[3BP]). Statistical analysis was performed by one-way ANOVA with Tukey’s post-hoc test comparing the K m and V max values of each cell line. *Significant differences with P < 0.05 (n=3).
Figure 2 Effect of protonophores and ionophores on the uptake of 1 mM radiolabelled 3BP at pH 6.0
CCCP and monensin were used at 100 μM and valinomycin at 50 μM. The results are presented using as reference the uptake of 1 mM 3BP without other compound addition (control). Statistical
analysis was performed by one-way ANOVA with Dunnett’s post-hoc test comparing all drugs to the control condition. ***Significant differences with P < 0.001 (n=3).
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82% inhibition of uptake was observed whereas 52% inhibition
was found in both the ZR-75-1 and the MCF-7 cells. Monensin
and valinomycin were very effective as inhibitors of 3BP uptake in
the SK-BR-3 cells (57% and 65% inhibition respectively), with
small inhibitory effects on 3BP uptake in MCF-7 and ZR-75-1
cells. These results indicate that 3BP uptake requires a proton
gradient in the three cell lines and also an Na+ gradient in the
SK-BR-3 cell line.
The effect of MCT inhibitors on 3BP uptake and cytotoxicity
To further characterize the mechanism of 3BP transport and
its dependency on one or more MCTs, we tested classic MCT
inhibitors (Figure 3A) such as CHC, DIDS, the specifically
designed inhibitor AR-C155858, as well as 3BP’s natural
analogues pyruvate and L-lactate. CHC is an MCT-1 inhibitor
which also inhibits SMCT-1; DIDS inhibits MCTs and
anion exchangers; AR-C155858 is an inhibitor developed by
AstraZeneca specific for MCT-1 and MCT-2 in a mechanism that
involves intracellular binding at transmembrane helices 7–10 [30].
AR-C155858 inhibited 3BP uptake very strongly in both ZR-
75-1 cells (69%) and MCF-7 cells (79%) and only slightly in SK-
BR-3 cells (31%). The compound DIDS under these conditions
had a very weak effect on 3BP uptake, with no statistically
significant difference between the three cell lines (3% in ZR-
75-1, 13% in MCF-7 and 17% in SK-BR-3; Figure 3A).
When the experiments were performed in the presence of
10 mM lactate, cells retained 84% (ZR-75-1), 74% (MCF-7) and
65% (SK-BR-3) of their 3BP uptake capacity; on the other hand,
in the presence of pyruvate (10 mM) ZR-75-1 cells retained 67%,
MCF-7 51% and SK-BR-3 50% of their 3BP uptake capacity
compared with the control. Overall, these results indicate that both
ZR-75-1 and MCF-7 cells display a similar inhibitory pattern for
3BP uptake which probably relies on MCT-1 as AR-C155858 led
to a higher level inhibition in contrast with what is observed in
SK-BR-3 cells. Together with the data obtained with the use of
ionophores, it is possible to postulate that SK-BR-3 cells display
a mechanism for 3BP transport distinct from that used in both
ZR-75-1 and MCF-7 cells.
We also evaluated the effect of the MCT-1 inhibitor AR-
C155858 on the cytotoxic capacity of 3BP in ZR-75-1 and SK-
BR-3. The experiments were performed using low and high
doses of 3BP in combination with 1 μM inhibitor and the
results were expressed as percentage survival (Figures 3B and
3C respectively). In the ZR-75-1 cell line, 3BP alone decreased
cell survival as expected showing 89% with 30 μM, 66% with
60 μM and 18% with 150 μM. Treatment with the inhibitor AR-
C155858 led to an increase in cell survival to 92% at 30 μM,
88% at 60 μM and 86% at 150 μM 3BP (Figure 3B). In SK-
BR-3 cells, 79% survived with 250 μM 3BP, 62% with 500 μM
and 34% with 2000 μM and AR-C155858 did not affect the
normal cell growth. However, 3BP’s cytotoxic effect was further
compromised in the presence of the MCT-1 inhibitor at all 3BP
concentrations tested (Figure 3C). The increased resistance to
3BP treatment observed with AR-C155858-treated cells led us
to conclude that MCT-1 plays a crucial role in 3BP uptake, thus
affecting the cytotoxicity of 3BP as an anti-cancer agent.
Cytotoxicity of 3BP depends on extracellular pH
The cytotoxic effect of 3BP has been reported at pH 7.4 [27], in the
three cell lines analysed. As we have observed the influence of pH
on 3BP uptake, we re-evaluated its cytotoxicity in cells cultivated
in RPMI 1640 medium buffered with HEPES both at pH 6.0
and at pH 7.4 (Figure 4). Although the pattern of cytotoxicity
is maintained with ZR-75-1 cells being the most sensitive and
SK-BR-3 cells the most resistant to 3BP, the decrease in the
extracellular pH from 7.4 to 6.0 promoted a decrease in the IC50
values for 3BP cytotoxicity in all cell lines (34% for ZR-75-1,
19% for MCF-7 and 44% for SK-BR-3). These results clearly
reinforce the conclusion that tumour extracellular pH influences
the anti-cancer cytotoxicity of 3BP.
Metabolism-related proteins expression profiles
To better understand the mechanisms underlying the distinct range
of IC50 values for 3BP found for the three cells lines and how they
are associated with the mechanisms of transport of 3BP across
the plasma membrane, we analysed via Western blot analysis the
expression patterns of MCTs and related proteins, namely CD147,
CD44, AE1 and also Hk-2. The results presented in Figure 5 were
processed using β-actin as an internal control and the values are
presented, using as reference (100%), the expression profiles
found in the ZR-75-1 cell line as, with the exception of Hk-2,
this cell line always presented a higher level of expression of the
assayed proteins than the other cell lines.
Relative to the ZR-75-1 cell line, the expression levels of
MCT-1 were 69 +− 11% in MCF-7 and 82 +− 26% in SK-BR-3.
Relative to ZR-75-1 expression, MCT-4 expression was found to
be 10 +− 3% in MCF-7 and 39 +− 8% in SK-BR-3. The expression
of glycoprotein CD44 was found to be at similar levels in ZR-
75-1 and MCF-7 (82 +− 20%) and at lower levels in SK-BR-3(25 +− 1%). The chaperone CD147, important for MCT-1 and
MCT-4 activity, was present in both fully glycosylated (FG)
and core-glycosylated (CG) forms in ZR-75-1 at greater levels
than in MCF-7 (FG: 12 +− 4%, CG: 69 +− 11%) and in SK-BR-3(FG: − 13 +− 4%, CG: 12 +− 1%). Expression of anion exchanger
1 (AE1) was found in similar levels in ZR-75-1 and MCF-7
(29 +− 1%), but was not present in SK-BR-3 cells. Hk-2 was
present in all cell lines but at a low amount in MCF-7 (57 +− 25%)
and in higher levels in SK-BR-3 (264 +− 80%). Overall, regarding
the proteins assessed, it was found that SK-BR-3 cells, the most
resistant to a cytotoxic effect of 3BP, display a very low expression
for CD44, CD147 (both forms) and AE1 and a higher expression
of Hk-2 relative to ZR-75-1 and MCF7 cells.
Butyrate pretreatment on 3BP transport
We demonstrated previously that butyrate pretreatment of SK-
BR-3 cells leads to an increased cytotoxic effect of 3BP [27].
This phenotype was accompanied by the up-regulation of MCT-4
expression and an increased localization of MCT-1 in the plasma
membrane [27]. We hypothesized that butyrate may be altering
3BP transport. Therefore, we monitored the kinetics of 3BP uptake
for 24 h in the three different breast cancer cell lines, with and
without treatment with 10 mM butyrate (Figure 6). Significantly,
in all cell lines, we found an increased affinity for 3BP uptake via
a decrease in Km values (Figure 6B). However, only in the case
of the SK-BR-3 cell line was the decrease in the Km statistically
significant. In the SK-BR-3 cells, the Km for 3BP uptake shifts
from 2.16 to 0.65 mM demonstrating that the effect of butyrate
on this MCT’s expression is related directly to the cytotoxicity
of 3BP that increases the affinity for 3BP uptake. The Km for
SK-BR-3 cells treated with butyrate decreased to values similar
to those presented by the ZR-75-1 and MCF-7 cell lines without
butyrate treatment. Surprisingly, an increase in the glycosylation
of CD147 was found also under these conditions (Figure 7).
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Figure 3 Effect of MCT inhibitors on 3BP uptake and cytotoxicity
(A) Inhibition of radiolabelled 3BP (1 mM) uptake by AR-C155858 (1 μM), CHC (10 mM), pyruvate (10 mM) and lactate (10 mM) and DIDS (1 mM). The results are presented using as reference
the uptake of 1 mM of 3BP without other compound addition (control). (B) Effect of AR-C155858 (1 μM) in the cytotoxicity of 3BP in the ZR-75-1 cell line. (C) Effect of AR-C155858 (1 μM) in
the cytotoxicity of 3BP in the SK-BR-3 cell line. In (B and C) results are expressed as percentage survival assuming the condition without addition of any compound as 100 % survival. Statistical
analysis was performed by one-way ANOVA with Dunnett’s post-hoc test comparing all drugs to the control. ***, ** and * indicate significant differences with respective P-values of < 0.001, < 0.01
and < 0.05 (n=3).
Inhibition of CD147 glycosylation in ZR-75-1 cells
In order to understand how CD147 glycosylation influences the
uptake of 3BP, we attempted to inhibit its glycosylation in the
ZR-75-1 cell line, which present higher levels of CD147, using
tunicamycin. We could inhibit the glycosylation of de novo
synthesized CD147 as we were able to detect a band of 27 kDa
corresponding to the core protein CD147 without glycosylation
(CP) when tunicamycin is added (Figure 8A). The Western blots
for CD147 expression in each time point correspond to the same
membrane with a lower exposure time for the CP form and a higher
exposure time for FG and CG CD147 (Figure 8A). To overcome
the influence of the glycosylated CD147 already present in cells
by the time of treatment, we have evaluated different time points.
We could observe that the levels of CD147 FG and CG diminish
with time in cells treated with tunicamycin in comparison with
untreated cells (Figure 8A). The decrease in glycosylated CD147
was followed by a decrease in the expression of MCT-1 being
more evident for higher concentrations of tunicamycin.
The evaluation of 3BP uptake at 48 h of incubation with
tunicamycin resulted in a low, but statistically significant,
inhibition at the concentrations of 10 μg/ml (73%) and 20 μg/ml
(83%), but not at 2 μg/ml (96%) or 5 μg/ml (88%). At 72 h,
3BP uptake was significantly inhibited with 2 μg/ml (76%) and
20 μg/ml (75%) but not with 5 μg/ml (85%) and 10 μg/ml
(90%) of tunicamycin. At 96 h, tunicamycin successfully
inhibited 3BP uptake at all concentrations tested (2 μg/ml, 64%;
5 μg/ml, 51%; 10 μg/ml, 39%; 20 μg/ml, 14%).
DISCUSSION
The results of the present study focused on better understanding,
the underlying basis of the anti-cancer cytotoxicity 3BP, towards
breast cancer employing three different cell lines has led us to the
following four conclusions.
Extracellular acidic pH is important for 3BP selectivity
We have characterized the kinetics of 3BP uptake in breast cancer
cell lines ZR-75-1, MCF-7 and SK-BR-3 at pH 6.0 and 7.4
(Figure 1). These cells had been characterized previously for
3BP cytotoxicity [27] and found to present different levels of
sensitivity: ZR-75-1 > MCF-7 > SK-BR-3. The transport of 3BP
obeys classical Michaelis–Menten kinetics for one transporter,
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Figure 4 Effect of 3BP on cell viability of the breast cancer cell lines ZR-75-1, MCF-7 and SK-BR-3 at extracellular pH 6.0 or 7.4, evaluated by the SRB assay
(A) Graphic representation of the percentage survival as a function of the 3BP concentration after logarithmic transformation. (B) IC50 values estimated by applying a sigmoidal dose-response
(variable slope) non-linear regression (n=3).
but the cells’ behaviour differed at different pH values. Whereas
at pH 7.4 all cell lines presented a similar Km for 3BP, at pH 6.0
a significant difference was observed. The cell lines ZR-75-1
and MCF-7 that were more sensitive to 3BP presented a 4-fold
lower Km for 3BP transport than the SK-BR-3 cell line. This
result indicates that differences in affinity for 3BP uptake may
underlie its cytotoxic effect, i.e. cells with higher affinity (lower
Km) for 3BP uptake may be more prone to 3BP cytotoxicity.
From results obtained by studying the effect of protonophores and
ionophores on 3BP uptake (Figure 2), it was evident that at least
two mechanisms may be involved in its transport. In the cell lines
ZR-75-1 and MCF-7, a proton-linked symport occurs, whereas
in the cell line SK-BR-3, a pH-independent transport mechanism
is also present, most probably a sodium-linked mechanism. We
have also evaluated the influence of glucose concentration in
the 3BP uptake buffers. As described by Sonveaux et al. [31],
tumours are metabolically heterogeneous presenting glycolytic
and oxidative regions between which a lactate MCT-1 pathway
exists. As glucose availability can alter the metabolic profile and
MCT expression, we have measured the kinetics of 3BP uptake
in the presence and absence of glucose in ZR-75-1 and SK-BR-3
cell lines. In both cells, the kinetics of 3BP uptake followed the
same pattern observed either in the presence or in the absence of
glucose, without alterations regarding affinity or velocity of 3BP
transport (results not shown).
There are several studies in normal and in cancer cells that
have reported the uptake of monocarboxylic acids, including
3BP, through MCTs. Most report that at extracellular pH 5.5–
6.5, the uptake of carboxylic acids by MCTs is considerably
higher than that observed at pH 7.0–7.5 [26,29,32]. In the present
study, we show for the first time that at pH 6.0, the affinity for
3BP transport is higher than at physiological pH (i.e. pH 7.4).
This fact is important for better understanding the mechanism
of 3BP’s effective and rapid killing action towards cancer and
perhaps important also in giving a crucial clue to understanding
the absence of noticeable side effects observed in in vivo studies
in normal tissues [24]. Due to its high glycolytic phenotype, a
tumour’s extracellular environment is commonly acidic, a feature
that promotes 3BP’s action including its transport by MCTs
through the plasma membrane of cancer cells with high affinity.
We also observed that 3BP cytotoxicity is about the same at both
pH 6.0 and 7.4, but with a higher sensitivity at pH 6.0 (Figure 4).
At pH 7.4, the transport of 3BP occurs with lower affinity. This
suggests that higher doses of 3BP may be needed relative to those
used at pH 6.0. Thus, it is possible to postulate that under the
in vitro conditions used in the present study, we also have to
take into account the fact that, even at pH 7.4, cancer cells will
metabolize glucose to lactate which is then exported coupled with
protons. This will lead to a reduction in pH of the external medium
favouring the uptake of 3BP. The higher the proton availability
in the extracellular environment, the more the inward symport
flux of protons will be favoured and thus 3BP-mediated uptake
via MCTs. Therefore, based on our results, we propose that the
specific cytotoxic effect of 3BP towards cancer cells is directly
related to its transport across the plasma membrane dependent
on an acidic extracellular pH that increases the affinity for 3BP
uptake. In addition, we speculate that the results of the present
study may be very significant in designing future anti-cancer 3BP
treatment protocols for cancer patients in a clinical setting. Due
to the high affinity and selectivity of cancer cells for 3BP uptake,
low dosages can be used, thus avoiding potential side effects and
systemic treatments should be less problematic.
Higher sensitivity to 3BP is accompanied by higher expression of
MCT-related proteins
The use of inhibitors of MCTs (Figure 3A) indicates that in
the ZR-75-1 and MCF-7 cells the transport of 3BP occurs
via MCTs, with MCT-1 being the most probable player. Thus,
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Figure 5 Expression analysis of MCT-1, MCT-4, CD147, CD44, AE1 and Hk-2 in ZR-75-1, MCF-7 and SK-BR-3 breast cancer cell lines cultured in RPMI 1640
medium until 80% confluence was reached
(A–C) Western blot of all proteins tested as indicated to the left of the blots. β-Actin was used as a loading control. A representative experiment of at least three independent experiments is shown.
(D) Quantification of protein levels. Bands were quantified using ImageJ software and values are expressed as means +− S.E.M. for at least three independent experiments as a percentage using as
reference ZR-75-1 (100 %) (n=3).
the use of MCT-1’s specific inhibitor AR-C155858 led to a
substantial inhibition of 3BP transport in these cell lines (75–
80% respectively). Interestingly, however, in the SK-BR-3 cell
line AR-C155858 inhibits 3BP uptake by only 25% (Figure 3A).
This result is consistent with the behaviour of this cell to the
ionophores monensin and valinomycin and reinforces the action
of another transport system, distinct from MCTs. The use of
the MCT-1 inhibitor AR-C155858 shows that this inhibitor is
able to increase the resistance of cells to 3BP (Figures 3B and
3C). This indicates a direct relationship between 3BP transport
and its cytotoxicity. MCTs, especially MCT-1, are responsible
for 3BP uptake that determines the cytotoxic effect of 3BP. We
can conclude that if this transport system is blocked, 3BP will
not cross the plasma membrane efficiently and cells become
resistant to its effects. Although unlikely, we cannot exclude
the possibility that some 3BP may enter cells via passive
diffusion.
3BP is a substrate of SMCT-1 [28], encoded by the gene
SLC5A8, the expression of which is down-regulated in many
types of cancer. SCMT-1 is now being considered a tumour
suppressor [33]. However, we cannot exclude the involvement
of SMCT-1 as the sodium-linked symporter for 3BP found in
SK-BR-3 cells.
In order to exploit the hypothesis raised, we assessed the
expression profiles for MCT-1, MCT-4 and other proteins
important for MCTs activity, such as the chaperones CD147 and
CD44, as well as the pH regulator AE1 (Figure 5). In addition
to these proteins, we also assessed the expression of SMCT-1.
However, the antibodies commercially available did not give a
specific pattern of labelling (results not shown).
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Figure 6 Effect of butyrate treatment on the kinetics of radio labelled 3BP uptake in the breast cancer cell lines ZR-75-1, MCF-7 and SK-BR-3
(A) Michaelis–Menten plots of the initial uptake rates of radio labelled 3BP uptake, as a function of the acid concentration at pH 6.0. Black symbols refer to untreated condition and open symbols to
cells treated with 10 mM of butyrate. (B) Kinetic parameters, as affinity constant (K m) and transport capacity (V max) for the uptake of 3BP. Values were estimated with GraphPad Prism software based
on the non-linear regression for the Michaelis–Menten equation f [V] = (V max × [3BP])/(K m + [3BP]). Statistical analysis was performed by one-way ANOVA with Tukey’s post-hoc test comparing
the K m and V max values of each cell line. *Significant differences with P < 0.05 (n=3).
Figure 7 Effect of butyrate treatment on CD147 in breast cancer cell line SK-BR-3
(A) Western blot of CD147 using β-actin as a loading control in cells untreated (control) and treated with 10 mM butyrate. (B) Quantification of protein levels. Bands were quantified using ImageJ
software and values are expressed in comparison with the control sample without butyrate addition (n=3).
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Figure 8 Influence of inhibition of CD147 glycosylation with tunicamycin on 3BP uptake in breast cancer cell line ZR-75-1
(A) Western blot of MCT-1 and CD147 using β-actin as a loading control at 48, 72 and 96 h of incubation with tunicamycin. For CD147 detection a low exposure time was used for the CP form and
a high exposure time was used for the FG and CG forms of CD147. (B) Inhibition of radiolabelled 3BP (1 mM) uptake by tunicamycin at 2, 5, 10 and 20 μg/ml after 48, 72 and 96 h of treatment.
Statistical analysis was performed by two-way ANOVA: ***, ** and * indicate significant differences with a respective P-values of < 0.001, < 0.01 and < 0.05 (n=3).
It is known that MCT-1 and MCT-4 activity in the plasma
membrane rely on their association with a glycosylated form
of CD147 [34]. The binding of CD147 to carbonic anhydrase
IV in the extracellular environment has also been reported
[35] and that carbonic anhydrases function as proton-collecting
antennae supplying protons essential for the activity MCTs
[36]. The higher expression of the FG active form of CD147
was observed in ZR-75-1 cells, reinforcing its role on MCT-
1 and MCT-4 activity and thus in 3BP uptake in these
cells.
Another interesting observation was the expression of AE1
found in both ZR-75-1 and MCF-7 cells and its absence from
SK-BR-3 cells. AE1 is a known anion exchanger of chloride and
bicarbonate, but it was first reported to be involved in the transport
of lactate in erythrocytes. Therefore, it may also have a role in 3BP
transport. However, we cannot exclude an indirect role for AE1 in
proton movement across the plasma membrane, resulting in the
activation of an inward flux via MCTs or even its own involvement
in the 3BP uptake. The expression of Hk-2, a known target of 3BP
[22], was found to be higher in SK-BR-3 cells, the cell line most
resistant to 3BP, i.e. more resistant than cell lines ZR-75-1 and
MCF-7. Although the SK-BR-3 cell line presented higher levels
of Hk-2 expression, the sensitivity to 3BP can also be related
with other intracellular targets such as GAPDH and, as shown in
the present study, the equilibrium between acidic extracellular pH
and MCT activity is important for 3BP selectivity and sensitivity
to cancer cells.
Butyrate increases the affinity of 3BP transport in SK-BR-3
Butyrate’s anti-cancer properties have been reported previously
[37]. However, the molecular mechanism(s) underlying its anti-
cancer properties are still unsolved. Nevertheless, some important
advances have been made [38]. Butyrate has a dual role. In normal
cells, such as colonocytes, it is used as an energy source, having a
positive effect leading to proliferation and differentiation. On the
other hand, in colon cancer cells that present the Warburg effect,
high concentrations of butyrate are able to initiate apoptotic events
[38]. Our previous data showed that butyrate has the ability to
sensitize the 3BP-resistant cell line SK-BR-3 to the effect of 3BP
by inducing an increased expression of MCT-4 and an enhanced
level of MCT-1 localization at the plasma membrane [27]. In
addition, we observed that the CD147 expression profile changed
with an enhancement of glycosylation upon treatment of cells with
butyrate (Figure 7). Finally, we demonstrated that these events are
accompanied also by an increase in the affinity for 3BP uptake
(Figure 6). This indicates that the effect of butyrate in mediating
3BP uptake is related not only to the over-expression of MCTs at
the plasma membrane as previously demonstrated [27], but also
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accompanied by an increase in the affinity for its transport across
the plasma membrane. Thus, butyrate sensitizes SK-BR-3 cells to
3BP by promoting MCT-1 re-localization to the plasma membrane
with CD147 glycosylation contributing to MCT-1 activity that
ultimately promotes cells’ uptake of 3BP with increased affinity.
Inhibition of CD147 glycosylation affects 3BP uptake in ZR-75-1
Our data showed that butyrate stimulated the glycosylation of
CD147 and thus we hypothesized that this could lead to an
increase in the expression levels of MCT-1 and consequently
to the observed higher affinity of 3BP uptake in the resistant
cell line SK-BR-3 (Figure 6). To provide further independent
evidence on the importance of CD147 glycosylation for MCT-1
expression and activation, we inhibited glycosylation of CD147
using tunicamycin. This compound is a known inhibitor of N-
glycosylation and has been previously used to inhibit CD147
glycosylation [39]. In the present study, we have used the ZR-75-
1 cell line, as in contrast with SK-BR-3, it presents higher levels
of CD147 as well as higher affinity for 3BP uptake. Our results
demonstrate that inhibition of CD147 glycosylation resulted in
a decrease in 3BP uptake (Figure 8). The effect was more
pronounced with the increased time of exposition to tunicamycin
as some active CD147 remains in cells, probably due to a high
stability of this protein at the plasma membrane. We could also
demonstrate that alterations in CD147 glycosylation lead to a
decrease in the expression levels of MCT-1. This observation was
expected since these two proteins are tightly associated, being
important for monocarboxylic acid uptake [34]. Taken together,
the results obtained in both cell lines ZR-75-1 and SK-BR-3
regarding CD147 glycosylation make is possible to postulate
that the presence of glycosylated CD147 is crucial for MCT-1-
mediated transport of 3BP across the plasma membrane. Our data
suggest for the first time that glycosylated CD147 is a key factor
on the control of the expression levels of MCT-1 and consequently
the uptake of 3BP.
Final remarks
The alkylating agent 3BP has been proposed as a novel anti-cancer
drug that targets one of the oldest known phenotypes of cancer,
i.e. the Warburg effect. By targeting both key glycolytic enzymes
overexpressed in cancers, such as Hk-2 and GAPDH, as well as
other targets in mitochondria [23], 3BP is a good candidate for
inducing a metabolic catastrophe in cancer cells [40]. Although
the highly reactive nature of 3BP may make it appear unsuitable as
an anti-cancer agent, several in vivo studies have reported low or
no major side effects [22,25,41,42]. The overexpression of MCT-
1 and MCT-4 in tumours has been noted not only by our group
but also by others to be a key player in 3BP transport across the
plasma membrane, with a major role attributed to MCT-1 in this
process [26,27,43].
In the present study, we show for the first time in cancer
cells that the mediated transport of 3BP by MCTs, especially
MCT-1 associated with CD147 glycosylation, is a key factor
in 3BP’s selective anti-cancer effect; however, this is not the
only event involved. Our novel results showed that the acidic
extracellular pH, which characterizes the tumour extracellular
microenvironment, is also crucial for the selective action of 3BP
explaining the selectivity of this potent and promising anti-cancer
agent. The acidic microenvironment is a double-edged sword.
On the one hand, it provides an advantage for the cancer cells
by favouring proliferation and metastasis. However, on the other
hand, in the world’s fight against cancer, it can be envisaged as
an ‘Achilles heel’ of cancer that can be further explored with the
objective of designing/developing new therapeutic approaches to
target this hallmark of the cancer, i.e. the Warburg effect.
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